Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 14
2003 12
2004 23
2005 25
2006 32
2007 34
2008 38
2009 47
2010 45
2011 55
2012 80
2013 96
2014 114
2015 135
2016 163
2017 156
2018 164
2019 182
2020 249
2021 267
2022 304
2023 307
2024 327
2025 157

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,691 results

Results by year

Filters applied: . Clear all
Page 1
Hypoxia inducible factor-1α drives cancer resistance to cuproptosis.
Yang Z, Su W, Wei X, Pan Y, Xing M, Niu L, Feng B, Kong W, Ren X, Huang F, Zhou J, Zhao W, Qiu Y, Liao T, Chen Q, Qu S, Wang Y, Guan Q, Li D, Zen K, Chen Y, Qin C, Wang Y, Zhou X, Xiang J, Yao B. Yang Z, et al. Among authors: chen y. Cancer Cell. 2025 May 12;43(5):937-954.e9. doi: 10.1016/j.ccell.2025.02.015. Epub 2025 Mar 6. Cancer Cell. 2025. PMID: 40054467
Tranilast directly targets NLRP3 to treat inflammasome-driven diseases.
Huang Y, Jiang H, Chen Y, Wang X, Yang Y, Tao J, Deng X, Liang G, Zhang H, Jiang W, Zhou R. Huang Y, et al. Among authors: chen y. EMBO Mol Med. 2018 Apr;10(4):e8689. doi: 10.15252/emmm.201708689. EMBO Mol Med. 2018. PMID: 29531021 Free PMC article.
Targeting JMJD1C to selectively disrupt tumor Treg cell fitness enhances antitumor immunity.
Long X, Zhang S, Wang Y, Chen J, Lu Y, Hou H, Lin B, Li X, Shen C, Yang R, Zhu H, Cui R, Cao D, Chen G, Wang D, Chen Y, Zhai S, Zeng Z, Wu S, Lou M, Chen J, Zou J, Zheng M, Qin J, Wang X. Long X, et al. Among authors: chen y. Nat Immunol. 2024 Mar;25(3):525-536. doi: 10.1038/s41590-024-01746-8. Epub 2024 Feb 14. Nat Immunol. 2024. PMID: 38356061
Combined proteomics and single cell RNA-sequencing analysis to identify biomarkers of disease diagnosis and disease exacerbation for systemic lupus erythematosus.
Li Y, Ma C, Liao S, Qi S, Meng S, Cai W, Dai W, Cao R, Dong X, Krämer BK, Yun C, Hocher B, Hong X, Liu D, Tang D, He J, Yin L, Dai Y. Li Y, et al. Among authors: yun c. Front Immunol. 2022 Nov 29;13:969509. doi: 10.3389/fimmu.2022.969509. eCollection 2022. Front Immunol. 2022. PMID: 36524113 Free PMC article.
An engineered IL-2 partial agonist promotes CD8+ T cell stemness.
Mo F, Yu Z, Li P, Oh J, Spolski R, Zhao L, Glassman CR, Yamamoto TN, Chen Y, Golebiowski FM, Hermans D, Majri-Morrison S, Picton LK, Liao W, Ren M, Zhuang X, Mitra S, Lin JX, Gattinoni L, Powell JD, Restifo NP, Garcia KC, Leonard WJ. Mo F, et al. Among authors: chen y. Nature. 2021 Sep;597(7877):544-548. doi: 10.1038/s41586-021-03861-0. Epub 2021 Sep 15. Nature. 2021. PMID: 34526724 Free PMC article.
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
Huang J, Xu J, Chen Y, Zhuang W, Zhang Y, Chen Z, Chen J, Zhang H, Niu Z, Fan Q, Lin L, Gu K, Liu Y, Ba Y, Miao Z, Jiang X, Zeng M, Chen J, Fu Z, Gan L, Wang J, Zhan X, Liu T, Li Z, Shen L, Shu Y, Zhang T, Yang Q, Zou J; ESCORT Study Group. Huang J, et al. Among authors: chen y. Lancet Oncol. 2020 Jun;21(6):832-842. doi: 10.1016/S1470-2045(20)30110-8. Epub 2020 May 13. Lancet Oncol. 2020. PMID: 32416073 Clinical Trial.
Advances in HER2 testing.
Chen Y, Liu L, Ni R, Zhou W. Chen Y, et al. Adv Clin Chem. 2019;91:123-162. doi: 10.1016/bs.acc.2019.03.004. Epub 2019 May 10. Adv Clin Chem. 2019. PMID: 31331487 Review.
2,691 results